Revenue: As of FY2025 Q2, the actual value is USD 5.218 M.EPS: As of FY2025 Q2, the actual value is USD -0.21.<h3>Healthcare Segment</h3><ul><li>Net Revenues: $5.2 million for the three months ended June 30, 2025, compared to $20,187 for the same period in 2024. For the six months ended June 30, 2025, net revenues were $8.4 million compared to $20,187 in 2024. The increase is primarily due to the acquisition of Myrtle and RCHI, with RCHI contributing $7.4 million in the six months ended June 30, 2025.</li><li>Operating Expenses: $3.9 million for the three months ended June 30, 2025, compared to $88,244 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $7.9 million compared to $88,244 in 2024.</li><li>Segment Earnings (Loss): $1.3 million for the three months ended June 30, 2025, compared to a loss of $66,723 for the same period in 2024. For the six months ended June 30, 2025, segment earnings were $0.4 million compared to a loss of $66,723 in 2024.</li></ul><h3>Labs Segment</h3><ul><li>Net Revenues: $7,816 for the three months ended June 30, 2025, compared to $7,287 for the same period in 2024. For the six months ended June 30, 2025, net revenues were $16,305 compared to $14,467 in 2024.</li><li>Operating Expenses: $41,259 for the three months ended June 30, 2025, compared to $718,078 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $72,753 compared to $884,708 in 2024.</li><li>Segment Loss: $33,443 for the three months ended June 30, 2025, compared to $710,791 for the same period in 2024. For the six months ended June 30, 2025, segment loss was $56,448 compared to $870,241 in 2024.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Healthcare Segment: The company plans to grow this division by acquisition and investment in new operations in targeted areas.</li><li>Myrtle Recovery Centers, Inc.: Plans to expand the business model by acquiring additional operating facilities and replicating the model in other rural hospital properties or suitable premises.</li><li>FOXO Labs: Focus on commercializing epigenetic biomarker technology and pursuing the spin-off of its FOXO Labs, Inc. subsidiary.</li></ul>

FOXO TECHNOLOGIES INC | 10-Q: FY2025 Q2 Revenue: USD 5.218 M